Bausch Health's rifaximin an Orphan Drug in U.S. for sickle cell disease

• The FDA grants Orphan Drug Designation to Bausch Health Companies (NYSE:BHC) and its gastroenterology business, Salix Pharmaceuticals', rifaximin for the treatment of sickle cell disease.
• Among the benefits of Orphan Drug status in the U.S. is a seven-year period of market exclusivity for the indication, if approved.
• Sickle cell disease is a group of inherited red blood cell disorders that affect hemoglobin.
• https://seekingalpha.com/news/3628896-bausch-healths-rifaximin-orphan-drug-in-u-s-for-sickle-cell-disease